Tagged with

China This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s USD 670mn global out-licensing deal, new funding rounds for Vibrant and InxMed, and major clinical wins including Akeso’s NSCLC bispecific,…

China Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting products to building real global brands means investing in strategic international talent acquisition and well-defined roles, all underpinned by a…

Europe The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains rocky, communication is patchy, and the wider impact on access and innovation is still murky. Writing in DIA’s Global Forum…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…

France Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial investments exceeding EUR 2.3 billion, the establishment of France as a global manufacturing hub for next-generation diabetes and obesity treatments,…

Switzerland Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at Lonza where she witnessed the evolution of the contract development and manufacturing organisation (CDMO) industry from a traditional service provider…

Switzerland Stephan Fritschi, recently appointed CEO at CARBOGEN AMCIS, brings nearly three decades of institutional knowledge to his new position. With 29 years of experience within the organisation, he has witnessed the company’s evolution through multiple market cycles and strategic transformations. His appointment represents continuity in leadership while signalling a new…

USA Jennifer Hawks Bland, CEO of NewYorkBIO, discusses the rapid growth and transformation of New York’s life sciences ecosystem, emphasizing the importance of policy advocacy, capital formation, and access to innovation. As New York continues to build a strong foundation for biopharma and biotech, Hawks Bland highlights how the organization is…

Agentina Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are positioning themselves as regional leaders in biosimilars, vaccines, and clinical research, despite persistent inflation and global supply chain pressures. From…

Alexion Dana Vigier, Regional Vice President at Alexion, AstraZeneca Rare Disease blends clinical training as a French general practitioner with broad pharmaceutical leadership experience. Formerly President of the French Pharma Association in Oncology and a Global Franchise leader at AstraZeneca, she now oversees Alexion’s operations across Central and Northern Europe, including…

Switzerland Dr. Roch Ogier, CEO of OM Pharma, brings a strong background spanning clinical medicine, neuroscience research, and leadership roles at Sanofi-Aventis, Vifor Pharma, and Novartis. Over the past eighteen months, he has driven solid growth and positioned the company as a leader in bacterial lysates, innovative therapies derived from selected…